OSE Immunotherapeutics and Boehringer Ingelheim announced a major expansion of their partnership. Two new projects to develop first-in-class treatments wi...
CUPID is a Phase I safety and dosimetry study of TLX592, Telix’s investigational antibody-based targeted alpha therapy for prostate cancer. Establ...
The designation is based on Phase III INAVO120 results, showing the inavolisib-based regimen more than doubled progression-free survival compared with pa...
AstraZeneca intends to build a $1.5 billion manufacturing facility in Singapore for antibody drug conjugates (ADCs), enhancing global supply of its ADC por...
May is Hepatitis Awareness Month, the perfect time for individuals to talk to their health care providers about hepatitis vaccinations. Hepatitis is an inf...
bioLytical Laboratories Inc. announced today the immediate availability of its INSTI® HCV Antibody Test in the Australian market. The INSTI He...
InnoCare Pharma, a leading biopharmaceutical company dedicated to revolutionizing the treatment of cancer and autoimmune diseases, proudly announces ...
As the first NGS interpretation platform for both oncology and hereditary applications, the updated version of QIAGEN Clinical Insight Interpret is appro...
Genentech, a member of the Roche Group announced positive results from the Phase Ib clinical trial of CT-388, a dual GLP-1/GIP receptor agonist being...
Thermo Fisher Scientific Inc., the world leader in serving science, introduced the Applied Biosystems™ Axiom™ BloodGenomiX™ Array* a...
Atraverse Medical, a San Diego-based medical device company, announces the FDA clearance of its HOTWIRE™ radiofrequency (RF) guidewire, a novel devic...
BenevolentAI (“BenevolentAI” or the “Company”) (Euronext Amsterdam: BAI), a leader in applying advanced AI to accelerate biopharma ...
Baxter International Inc. (NYSE: BAX), a pioneer in nutrition therapy, proudly announces the United States Food and Drug Administration (FDA) approval of a...
Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) communicated today that the National...
© 2025 Biopharma Boardroom. All Rights Reserved.
